Please assess the completion status of the following clinical trial:

Trial Title: Effect of Apelin on Insulin Sensitivity: Proof of Concept in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men aged 18 to 40 years.~* BMI between 25 and 30 kg / cm ² (excluding terminals).~* Free of known chronic disease and any medication (any medication within 30 days prior to the inclusion visit).~* Non-pathological ECG.~* Heart rate between 50 and 80 beats per minute rest.~* Complete Blood Count (CBC) with no significant anomaly in terms of the investigator.~* Liver function tests without clinically significant abnormalities in terms of the investigator.~* Renal function tests without clinically significant abnormalities in terms of the investigator.~* Serum electrolytes without clinically significant abnormalities in terms of the investigator.~* Fasting plasma glucose less than 1.1 g / l.~* HbA1c within the normal range (4-6%).~* Good peripheral vein (forearm and back of the hand).~* Agreement to participate in the establishment of a serum bank.~* Sedentary or practicing occasional physical activity.~* Ability to sign informed consent.~* Affiliation to a social security scheme.~Exclusion Criteria:~* Risk factor, treatment or ECG as recommended by International Conference on Harmonization E14 (ICH E14) Clinical Evaluation of QT / corrected QT interval (QTc Interval= Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs~* Repeated a QTc interval\> 450 ms measurement~* Risk factor: myocardial infarction, hypokalemia, family history of long QT syndrome~* Personal history of cancer.~* Positive HIV serology.~* Hepatitis B serology positive.~* Positive hepatitis C serology.~* Cognitive impairment or mental illness (at the discretion of the investigator).~* Chronic excessive alcohol consumption (consumption\> 30g/jour or 210g/week).~* Person under judicial protection, guardianship.~* Subject with a resting systolic blood pressure greater than 140 mm Hg and diastolic blood pressure greater than 90 mmHg~* Smoking\> 10 cig / day and can not be interrupted for 24 hours.~* Subject exclusion period of another protocol.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Apelin (Type: EXPERIMENTAL): An apelin clamp in which an apelin infusion will be administered prior to reference clamp
- Placebo (Type: PLACEBO_COMPARATOR): A clamp reference during which a placebo solution (saline solution) will be administered prior to apelin clamp

Based on this trial design, predict the completion outcome and termination type (if applicable).